Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML
January 8th 2024Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Read More